graph Evidence gap map comparisons
pembrolizumab based treatment
pembrolizumab alone
mHNSCC - L1 - all population 2   
Comparator:  vs cetuximab plus platin plus 5FU; 
Risk of bias:  low;   some concerns;   high;  NA;